Bring your single-cell tumor data. Get a ranked, testable read on the tumor–immune microenvironment in minutes — without writing a line of code.
Single-cell RNA-seq made the tumor–immune microenvironment measurable. Yet turning a dataset into an immunotherapy decision still takes a bioinformatician and weeks of hand-built analysis. General-purpose AI tools fabricate genes and numbers, so they can't be trusted for rigorous work.
Bring a single-cell tumor dataset
(.h5ad or 10x .h5) and MyImmunome returns an interpretable brief:
Hot / inflamed, cold / excluded, or immune-desert — anchored to a pan-cancer reference, not a black box.
Immunotherapy-response and immune-resistance composites, with the axes that drive each one.
Checkpoint and T-cell exhaustion read-outs, plus reinvigoration potential (stem-like vs terminal).
The immunosuppressive program — Tregs, MDSCs, M2-TAMs, metabolic or stromal barriers — shaping the microenvironment.
Candidate antigens, each backed by measured expression and tumor-vs-normal specificity.
Explore live, then export a self-contained brief you can download and share.
.h5ad or 10x .h5; your cell-type labels or ours. Public / de-identified data only — never PHI.
One click. Deterministic scoring against a pan-cancer atlas — no coding, no hand-tuning.
Explore the result live in an interactive dashboard, then export a shareable Tumor–Immune brief.
Archetypes and scores are calibrated against a pan-cancer reference, so a number means the same thing across datasets.
Every number is computed. The optional AI layer explains only real result tables — it never invents genes or values.
A wet-lab scientist runs it end-to-end. Minutes, not weeks.
Only de-identified, aggregate summaries ever reach a language model — never raw single-cell data and never a patient identifier.
Using the same engine that runs in the app, with no cohort-specific tuning, every major output was validated against public data with real clinical outcomes — immunotherapy response, overall survival, and target specificity. Open the reports:
The plain-language summary: every app output checked against real patient outcomes — response, survival across 19 cancers, and target specificity.
An interpretable tumor–immune scoring engine validated against immunotherapy response and survival across nineteen cancers.
The full set of figures and statistics behind the validation — ROC curves, survival models, and target-enrichment plots.
The live demo compares a hot tumor (clear-cell RCC) and a cold tumor (glioblastoma) side by side — one click, in your browser.
Launch the live demo →Academic immuno-oncology and immunology labs · translational and biotech IO teams · CROs. Bring us a single-cell tumor dataset and we return a Tumor–Immune Intelligence report — expert-led analysis available now. For access, a pilot, or any question, get in touch.
